Press Releases

Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

Media Update: Sanofi’s Foundation S and Sobi extend their partnership with the World Federation of Hemophilia Humanitarian Aid Program

Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

Press Release: Availability of the Q1 2025 Aide mémoire

Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

Media Update: AAD: new data advance Sanofi’s scientific leadership across innovative treatments for inflammatory skin diseases

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Press Release: Sanofi and CD&R sign Opella share purchase agreement

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid